Improving the Public-Private Partnership; Rethinking Medicare Part D
RAAP study shows how out-of-pocket (OOP) cap in the Medicare prescription drug benefit, Part D will help millions of beneficiaries and create a path to improved access.
Washington, D.C. (06-9-2022) – The Rare Access Action Project, (RAAP), released a new study reflecting the impact of high out of pocket (OOP) liability to beneficiaries seeking treatment for Rare Diseases through Medicare Part D. These patients, afflicted with conditions that impact fewer than 200,000 people, remain disproportionately vulnerable as the catastrophic copayments for those treatments often creates an insurmountable barrier for those affected.
